Dr Martino Picardo to lead Stevenage Bioscience Catalyst
pharmafile | December 1, 2010 | Appointment | Research and Development |Â Â Dr Martino Pacardo, Stevenage Bioscience Catalyst, appointment, research and developmentÂ
New UK science park Stevenage Bioscience Catalyst (SBC) has appointed Dr Martino Picardo as its first chief executive.
Dr Picardo joins from the University of Manchester Incubator Company (UMIC) and will take up his new post in February 2011
His 20 years’ experience in the pharmaceutical and biotechnology sector include serving as a non-executive director to the Board of UK Business Incubation, the UK’s leading professional body for the development and support of business incubation environments.
Dr Picardo said: “I am absolutely delighted to be taking up this new role. Although I am sad to be leaving friends and colleagues in UMIC, I am also looking forward to working with new colleagues in what will be a very exciting and unique opportunity for UK plc in drug discovery and development.”
SBC is a £38 million independent bioscience facility that will be run as a joint venture between the UK Department of Business, Innovation and Skills, GlaxoSmithKline, the Wellcome Trust, the East of England Development Agency and the Technology Strategy Board.
The science park will be located next to the GSK Research and Development campus in Stevenage and construction on the facility has already started.
Once up and running it aims to pioneer a culture of open innovation offering tenants access to state-of-the-art facilities and the networks and expertise of the sponsor organisations.
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …
